Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade C 77.92 2.34% 1.78
RARE closed up 2.34 percent on Thursday, August 16, 2018, on 77 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical RARE trend table...

Date Alert Name Type % Chg
Aug 15 Doji - Bullish? Reversal 2.34%
Aug 10 Calm After Storm Range Contraction 2.26%
Aug 9 180 Bearish Setup Bearish Swing Setup 1.62%
Aug 9 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.62%
Aug 9 Calm After Storm Range Contraction 1.62%
Aug 8 Calm After Storm Range Contraction 0.43%
Aug 8 Narrow Range Bar Range Contraction 0.43%
Aug 8 Up 3 Days in a Row Strength 0.43%
Aug 7 Slingshot Bearish Bearish Swing Setup 0.70%
Aug 7 Calm After Storm Range Contraction 0.70%

Older signals for RARE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Is RARE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 87.33
52 Week Low 41.67
Average Volume 492,231
200-Day Moving Average 59.1455
50-Day Moving Average 79.9243
20-Day Moving Average 78.0418
10-Day Moving Average 76.2145
Average True Range 3.2317
ADX 21.87
+DI 14.4864
-DI 21.8111
Chandelier Exit (Long, 3 ATRs ) 75.8049
Chandelier Exit (Short, 3 ATRs ) 79.4251
Upper Bollinger Band 82.9234
Lower Bollinger Band 73.1602
Percent B (%b) 0.49
BandWidth 12.510219
MACD Line -0.8506
MACD Signal Line -0.7165
MACD Histogram -0.1341
Fundamentals Value
Market Cap 3.32 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -11.56
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 82.84
Resistance 3 (R3) 82.40 80.31 82.02
Resistance 2 (R2) 80.31 79.06 80.54 81.75
Resistance 1 (R1) 79.12 78.29 79.72 79.56 81.47
Pivot Point 77.03 77.03 77.33 77.26 77.03
Support 1 (S1) 75.84 75.78 76.44 76.28 74.37
Support 2 (S2) 73.75 75.01 73.98 74.09
Support 3 (S3) 72.56 73.75 73.82
Support 4 (S4) 73.00